Advancing the future of cancer therapy
Our clinical-stage pipeline comprises dual-cytokine immuno therapeutic candidates, built on our proprietary Navigated Delivery ™ FHAB platform to address significant unmet medical needs across oncology
Taking this navigated delivery platform into improving and enhancing the next generation of ADCs, an early stage candidate has successfully completed preclinical Proof of Concept and the platform is ready to deliver candidates for clinical trials and for partnering with other innovator ADC companies that want to improve their therapeutic efficacy and safety.
Pipeline overview
We have leveraged our proprietary FHAB technology platform into immunotherapy assets and ADCs for cancer treatment, demonstrating the ability and power of the Navigated Delivery™ platform to produce improved and advanced therapeutics.
GDT-001 (IL12-FHAB)
Soft-Tissue Sarcomas (STS),
solid tumors
Phase 1a
GDT-002 (IL12-FHAB-IL15)
Solid tumors, bladder cancer
IND ready
GDT-003 (IL12-FHAB–IL-18)
Solid tumors
Pre-clinical
Clinical Trials
For more information on our clinical trials, please visit the following pages (note these are historical trials carried out by Sonnet Biotherapeutics on the single cytokine IL12+FHAB)
SB101
GDT-001 Dose Escalation in Patients with Advanced Solid Tumors and Soft Tissue Sarcomas
SB102
Study of GDT-001 (IL12-FHAB) in Healthy Adults
Interested in Partnering or Collaborating?
Guidant Biotherapeutics is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.